BridgeBio (BBIO) Q4 2025 earnings review
Attruby Launch Accelerates as R&D Engine Delivers
BridgeBio closed 2025 with a phenomenal operational performance. The commercial launch of Attruby (acoramidis) is officially a blockbuster-in-the-making, with Q4 net product revenue accelerating 35% sequentially to $146.0M. Beyond the commercial success, the company’s R&D engine validated its 'high probability of technical success' model by delivering three positive Phase 3 readouts in just over three months (BBP-418, encaleret, infigratinib). While cash burn and debt levels remain high, the transition from a clinical-stage biotech to a diversified commercial organization is well underway.
🐂 Bull Case
Attruby sales reached $146M in Q4, capping a $362M first full year on the market. With 7,804 unique patient prescriptions written by 1,856 unique prescribers, the drug is rapidly capturing share in the treatment-naïve ATTR-CM market.
Three Phase 3 successes (LGMD2I/R9, ADH1, achondroplasia) set the stage for three new potential blockbuster launches in late 2026/early 2027, massively expanding the company's revenue base and de-risking the pipeline.
🐻 Bear Case
Despite surging revenues, FY25 operating cash burn was $445.9M. The company has amassed a heavy debt load, including $855M in deferred royalty obligations and the recent issuance of $632.5M in 2033 convertible notes.
Selling, general, and administrative expenses nearly doubled YoY to $531.2M in FY25 to support the Attruby launch. Supporting three additional upcoming launches will require sustained, elevated commercial spending.
⚖️ Verdict: 🟢
Bullish. The execution on Attruby is flawless and the Phase 3 pipeline delivery is highly impressive. The heavy debt and operating burn are concerns, but the revenue trajectory points to a clear path toward profitability.
Key Themes
Attruby Commercial Execution
Accelerating. Attruby continues to exceed expectations. Sequential product revenue growth remained robust: $36.7M (Q1) → $71.5M (Q2) → $108.1M (Q3) → $146.0M (Q4). The growth is supported by clinical superiority messaging, particularly the ≥90% TTR stabilization rate and superior outcomes in variant ATTR-CM populations. BridgeBio is successfully capturing a high share of treatment-naïve patients in a rapidly expanding TAM.
Triple Phase 3 Success Validates R&D Model
Stable. Management's claim of a >70% probability of technical success was validated by three pivotal readouts. BBP-418 (FORTIFY) showed a 2.6-point NSAD improvement for LGMD2I; Encaleret (CALIBRATE) achieved all primary/secondary endpoints in ADH1; and Infigratinib (PROPEL 3) demonstrated superior AHV (+2.10 cm/year) in achondroplasia. These successes pivot the company toward an aggressive multi-product regulatory filing strategy in 2026.
First-in-Class Innovation: Infigratinib
Accelerating. The PROPEL 3 readout for infigratinib marks a significant innovation milestone: the first statistically significant improvement in body proportionality in achondroplasia. As a daily oral, needle-free option, it has a distinct competitive advantage in the pediatric market over existing injectable therapies.
SG&A Expense Escalation Outpaces R&D
Accelerating. The shift from clinical to commercial stage is expensive. SG&A costs surged from $94.7M in 24Q4 to $158.0M in 25Q4. For the full year, SG&A was $531.2M, eclipsing R&D ($451.9M). Preparing for three additional product launches in late 2026/2027 will prevent near-term operating leverage from fully materializing.
Capital Structure and Debt Load
Accelerating. Despite generating $502M in FY25 revenue, the company posted a net loss of $732.9M. To bridge the gap to profitability, BridgeBio relies heavily on debt. Deferred royalty obligations ballooned to $855.0M (up from $479.0M in 2024), and the company issued $632.5M in new 2033 convertible notes in Jan 2026. Interest expenses and noncash interest on royalties are eating into the bottom line.
Macro: Pricing and Payer Scrutiny
Stable. The macro environment for rare disease pricing remains tense. While Attruby is priced ~10% below tafamidis, the emergence of Alnylam's AMVUTTRA and potential future tafamidis generics create a complex payer landscape. Payers may eventually push back on covering high-cost combination therapies (stabilizer + knockdown), which is a key mid-to-long term risk.
Other KPIs
Accelerating. Up sequentially from $120.7M in Q3, driven almost entirely by the $143.1M YoY increase in net product revenue from Attruby. Royalty revenue also increased to $5.3M (driven by EU/Japan sales).
Stable. Despite massive revenue growth, the net loss remained flat sequentially compared to Q3's $(182.7)M and slightly improved from 24Q4's $(267.4)M. Noncash interest expense on deferred royalty obligations ($38.6M in Q4) weighed heavily on the bottom line.
Decelerating. Down from $681.1M at the end of 2024. Operating cash burn of $445.9M in FY25 was partially offset by complex debt refinancing, royalty sales, and the recent $632.5M post-close January 2026 note issuance.
Guidance
Following positive Phase 3 FORTIFY results and FDA recommendation to pursue traditional approval, the company plans a submission in 1H 2026, targeting a U.S. launch in late 2026/early 2027.
After a successful pre-NDA meeting with the FDA, BridgeBio is on track for a 1H 2026 NDA submission, positioning for a late 2026/early 2027 commercial launch.
Following successful PROPEL 3 results, NDA and MAA submissions are planned for the second half of 2026, with an anticipated launch in early to mid-2027.
Key Questions
Gross-to-Net Evolution
With the Attruby launch maturing past its first year, how are gross-to-net dynamics evolving as free trial and patient assistance programs normalize?
SG&A Leverage
SG&A expenses reached $158M this quarter. Can the current commercial infrastructure support the planned late-2026 launches of BBP-418 and encaleret, or should we model another step-up in SG&A?
Payer Dynamics on Combination Therapy
Have payers initiated any formal steps or utilization management protocols restricting the use of Attruby in combination with TTR knockdown therapies?
Debt Servicing Capacity
With noncash interest on deferred royalties reaching $125M in FY25, at what revenue run-rate do you expect to achieve positive operating cash flow to organically service this complex capital structure?